ACLX Arcellx
- 52.730
- +0.480+0.92%
- 54.190
- +1.460+2.77%
Arcellx News
Gilead's Kite, Arcellx Share Phase 3 Trial Design for CAR-T Multiple Myeloma Asset
Arcellx Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Arcellx Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Arcellx Q1 EPS $(0.14) Beats $(0.51) Estimate, Sales $39.26M Beat $20.67M Estimate
Arcellx (NASDAQ:ACLX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.51) by 72.55 percent. This is a 75.86 percent increase over losses of $(0.58) per
Arcellx | 10-Q: Quarterly report
Arcellx and Kite Continue Momentum With Advances in Anito-Cel Multiple Myeloma Program
-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody ---- Anito-c
Earnings Flash (ACLX) ARCELLX Posts Q1 Revenue $39.3M
04:00 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (ACLX) ARCELLX Posts Q1 Revenue $39.3M
Press Release: Arcellx Provides First Quarter 2024 Financial Results
Arcellx Provides First Quarter 2024 Financial Results REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 09, 2024-- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the
Arcellx 1Q Rev $39.3M >ACLX
Arcellx 1Q Rev $39.3M >ACLX
Arcellx to Participate in Two Upcoming Investor Conferences
Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management
Buy Rating and $81 Price Target for Arcellx Inc. Amidst Strong Market Potential and Strategic Gilead Partnership
Arcellx(ACLX.US) Officer Sells US$932.56K in Common Stock
$Arcellx(ACLX.US)$ Officer Heery Christopher sold 18,168 shares of common stock on May 1, 2024 at an average price of $51.3296 for a total value of $932.56K.Source: Announcement What is statement of c
Arcellx Insider Sold Shares Worth $932,557, According to a Recent SEC Filing
Christopher Heery, Chief Medical Officer, on May 01, 2024, sold 18,168 shares in Arcellx (ACLX) for $932,557. Following the Form 4 filing with the SEC, Heery has control over a total of 8,938 shares o
Should You Be Bullish on Arcellx (ACLX)?
Arcellx(ACLX.US) Director Sells US$522.26K in Common Stock
$Arcellx(ACLX.US)$ Director Ware Olivia C sold 9,402 shares of common stock on Apr 16, 2024 at an average price of $55.5477 for a total value of $522.26K.Source: Announcement What is statement of chan
Arcellx Insider Sold Shares Worth $522,260, According to a Recent SEC Filing
Olivia C Ware, Director, on April 16, 2024, sold 9,402 shares in Arcellx (ACLX) for $522,260. SEC Filing: https://www.sec.gov/Archives/edgar/data/1786205/000141588924011120/xslF345X03/form4-04182024_0
Buy Rating Backed by Potential Regulatory Tailwinds for Arcellx's CAR-T Therapy
Needham: Reiterates Arcellx (ACLX.US) rating and adjusted from buy to buy rating, target price is $81.00.
Needham: Reiterates Arcellx (ACLX.US) rating and adjusted from buy to buy rating, target price is $81.00.
Needham Reiterates Buy on Arcellx, Maintains $81 Price Target
Needham analyst Gil Blum reiterates Arcellx with a Buy and maintains $81 price target.
Arcellx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/11/2024 37.1% Needham → $81 Reiterates Buy → Buy 03/18/2024 37.1% Needham $72 → $81 Maintains Buy 03/14
Optimizing Investment Decisions: Unveiling the Buy Rating for Arcellx Inc.
Analysis
Price Target
No Data
